此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

BBT001在健康志愿者(HVS)和成人特应性皮炎(AD)中的研究

2026年9月26日 更新者:Bambusa Therapeutics

一项随机,盲目的,安慰剂对照,单次和多重剂量研究,以评估BBT001和AD患者的安全性,耐受性,药代动力学,免疫原性,药效学和临床活性

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

研究概览

地位

招聘中

详细说明

This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.

研究类型

介入性

注册 (估计的)

237

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Christchurch、新西兰
        • 招聘中
        • Optimal Clinical Trials Ltd - Christchurch
      • Upper Hutt、新西兰、5018
        • 招聘中
        • Pacific Clinical Research Network (PCRN) Wellington
        • 接触:
          • Tim Humphrey
    • Auckland
      • Grafton、Auckland、新西兰、1010
        • 招聘中
        • Optimal Clinical Trials Central Auckland
        • 接触:
          • Arna Letica
      • Otahuhu、Auckland、新西兰、2025
        • 撤销
        • Aotearoa Clinical Trials
      • Takapuna、Auckland、新西兰、0622
        • 招聘中
        • Pacific Clinical Research Network (PCRN) - Auckland
        • 接触:
          • Paul Hamilton
      • Lodz、波兰、91-347
        • 招聘中
        • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
      • Rzeszów、波兰、35-055
        • 招聘中
        • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
      • Warsaw、波兰、02-507
        • 招聘中
        • Państwowy Instytut Medyczny MSWiA
      • Wroclaw、波兰、50-566
        • 招聘中
        • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
    • Western Australia
      • Fremantle、Western Australia、澳大利亚、6160
        • 招聘中
        • Fremantle Dermatology
      • Perth、Western Australia、澳大利亚、6009
        • 完全的
        • Linear Clinical Research
    • California
      • Irvine、California、美国、92614
        • 招聘中
        • First OC Dermatology
    • New York
      • New York、New York、美国、10128
        • 招聘中
        • OptiSkin Medical
      • The Bronx、New York、美国、10455
        • 招聘中
        • Equity Medical, LLC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 72年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Key Inclusion Criteria

  1. Negative pregnancy tests for women of childbearing potential.
  2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
  3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
  4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

  1. Age of 18-65 years.
  2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
  3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

  1. Age of 18-72 years.
  2. Body mass index ≥16 kg/m², weight capped at 125 kg.
  3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
  4. Moderate to severe atopic dermatitis
  5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
  6. Atopic lesions cover ≥10% of body surface area (BSA)
  7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

  1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
  2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
  3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
  4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
  5. Abnormal Electrocardiogram (ECG) findings
  6. History of drug/alcohol abuse in the past 2 years.
  7. Donated >500mL blood within 2 months of screening.
  8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

  1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
  2. Receipt of immunoglobulin or blood products within 30 days.
  3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
  4. Chronic pruritus from conditions other than atopic dermatitis.
  5. Acute/treated infections or chronic skin infections.
  6. Current use of sedating antihistamines or corticosteroids.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Part A Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

实验性的:Part B Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in healthy volunteers.

BBT001 will be administered

实验性的:Part C Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

安慰剂比较:Part A Single Ascending Dose Placebo

A single dose of Placebo will be administered in healthy volunteers

Placebo will be administered

安慰剂比较:Part B Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in healthy volunteers.

Placebo will be administered

安慰剂比较:Part C Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

有源比较器:Part D Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

安慰剂比较:Part D Single Ascending Dose Placebo

A single dose of placebo will be administered in healthy volunteers

Placebo will be administered

有源比较器:Part E Multiple Ascending Dose BBT001 - Dose Level 1

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

安慰剂比较:Part E Multiple Ascending Dose Placebo

Multiple doses of placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

有源比较器:Part E Multiple Ascending Dose BBT001 - Dose Level 2

Multiple doses of BBT001 will be administered in patients with atopic dermatitis

BBT001 will be administered

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of participants with adverse events following single and multiple administration of BBT001
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in serum blood parameters
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Laboratory assessments include hematology, blood chemistry and coagulation test

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in vital sign measurements following treatment administration.
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Blood pressure and heart rate will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in physical examination following treatment administration.
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Physical examination will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in 12-lead ECG readings
大体时间:Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

12-lead ECG will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Maximum observed concentration of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Serum PK Tmax will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Area under the curve (AUC)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Area under the curve of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Volume of distribution (Vz)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Volume of distribution of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Total clearance (CL)
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Total clearance of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Elimination Half-life (t1/2).
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Elimination half-life of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
大体时间:At specified timepoints pre-dose and up to 169 days post first dose administration

Serum Anti-Drug Antibodies will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Lisa Li、Bambusa Therapeutics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年2月27日

初级完成 (估计的)

2027年2月28日

研究完成 (估计的)

2027年2月28日

研究注册日期

首次提交

2025年1月30日

首先提交符合 QC 标准的

2025年1月30日

首次发布 (实际的)

2025年2月5日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月26日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅